KR20160008752A - Functional food composition for treating vitiligo containing rhodiola sachalinensis as active ingredient - Google Patents
Functional food composition for treating vitiligo containing rhodiola sachalinensis as active ingredient Download PDFInfo
- Publication number
- KR20160008752A KR20160008752A KR1020140088831A KR20140088831A KR20160008752A KR 20160008752 A KR20160008752 A KR 20160008752A KR 1020140088831 A KR1020140088831 A KR 1020140088831A KR 20140088831 A KR20140088831 A KR 20140088831A KR 20160008752 A KR20160008752 A KR 20160008752A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- vitiligo
- active ingredient
- composition
- functional food
- Prior art date
Links
- 206010047642 Vitiligo Diseases 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 239000004480 active ingredient Substances 0.000 title claims description 16
- 235000013376 functional food Nutrition 0.000 title claims description 12
- 241000083902 Rhodiola sachalinensis Species 0.000 title abstract description 3
- 238000011282 treatment Methods 0.000 claims description 23
- 241001165494 Rhodiola Species 0.000 claims description 16
- 230000036541 health Effects 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Natural products O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 2
- 235000001497 healthy food Nutrition 0.000 abstract description 2
- 210000002752 melanocyte Anatomy 0.000 description 17
- 238000000034 method Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000003902 lesion Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002087 whitening effect Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 210000001061 forehead Anatomy 0.000 description 3
- 239000003504 photosensitizing agent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000037922 refractory disease Diseases 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 101100505672 Podospora anserina grisea gene Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 244000055706 Renanthera elongata Species 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 241000327150 Rhodiola angusta Species 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 241000271499 Rigifila ramosa Species 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- -1 ethanol Chemical compound 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Abstract
Description
본 발명은 백반증 치료용 건강기능식품 조성물에 관한 기술로서, 특히, 유효성분으로 홍경천 추출물을 포함하는 것을 특징으로 하는 건강기능식품 조성물에 관한 것이다.
TECHNICAL FIELD The present invention relates to a health functional food composition for treating vitiligo, and more particularly, to a health functional food composition comprising an active ingredient (s) as an active ingredient (s).
본 발명은 백반증 치료 효과를 갖는 건강기능식품 조성물에 관한 기술이다.
The present invention relates to a health functional food composition having an effect of treating vitiligo.
백반증은 멜라닌세포 소실에 의해 다양한 크기와 형태의 백색반들이 피부에 나타나는 후천성 탈색소질환 중 가장 흔한 질환으로, 인구의 약 0.5 ~ 2%에서 나타나며 인종이나 지역에 차이 없이 발생하고, 대개 10 ~ 30세 사이에 자주 발생하는 질병이다.
It is the most common of the acquired decolorizing diseases of the skin with various size and shape due to melanocyte disappearance. It occurs in about 0.5 ~ 2% of the population and occurs without any difference in race or area. It is a common disease among the three.
멜라닌세포의 사망으로 피부가 희게 변색하는 백반증은 미용상 매우 중요한 난치성 질환으로 아직 효과적인 치료제가 개발되어 있지 않다. 현재 치료 방법으로는 스테로이드 치료, 광화학요법, 단파장 자외선B 치료, 표적 광치료, 외과적 방법 등이 알려져 있다.
Melanocyte dead skin pigmentation of the skin is a very important cosmetic intractable disease, yet there is no effective remedy developed. Current treatments include steroid therapy, photochemotherapy, short wavelength ultraviolet B treatment, target phototherapy, and surgical procedures.
스테로이드 치료는 병변이 작은 경우 스테로이드 연고제의 국소 도포, 트리암시놀론 국소 주사, 병변이 광범위한 경우 전신 스테로이드를 경구 투여하는 방법이다.
Steroid therapy is topical application of steroid ointment, topical injection of triamcinolone, and oral administration of systemic steroids if the lesion is extensive.
광화학요법 중 전신 광화학 요법은 광민감제인 소랄렌을 복용하고 2시간 후 자외선A를 조사하는 방법으로 대개 광선 조사량을 점차 늘려가며 일주일에 2 ~ 3회 시행하게 되며, 침범부위가 몸 전체의 1 ~ 2% 이내인 경우 광민감제를 국소도포하고 1시간 후 자외선A를 조사하는 국소 광화학요법을 이용할 수도 있다.
Photochemotherapy in photochemotherapy is a method of irradiating ultraviolet light A 2 hours after taking psoralen, a photosensitizer, and it is usually performed 2 ~ 3 times a week, gradually increasing the dose of light, If it is within 2%, topical photochemotherapy may be used to topically apply the photosensitizer and
단파장 자외선B 치료는 광화학요법과 달리 광민감제의 복용이나 도포가 필요 없이 311nm 근처의 파장을 방출하는 단파장 자외선B를 병변 부위에 조사하는 치료법이다.
Unlike photochemotherapy, short-wavelength ultraviolet B treatment is a treatment for irradiating a lesion site with a short-wavelength ultraviolet ray B which emits a wavelength near 311 nm, without taking or application of a photosensitizer.
표적 광치료는 전신 광치료 기계 이용으로 인한 불필요한 부위의 자외선 노출을 최대한 줄이면서 병변부위에만 치료하는 방법으로 엑시머 레이저 등이 최근 많이 이용되고 있다.
Recently, excimer laser has been widely used as a method to treat only the lesion area while minimizing the ultraviolet exposure of the unnecessary part due to the use of the whole-body photo-treatment machine.
외과적 방법으로 박피술, 중간층 피부이식, 펀치 이식, 흡입수포술 등을 이용한 피부이식술과 자가 멜라닌세포 이식 등이 이용되고 있다.
Skin transplantation and autologous melanocyte transplantation have been used by surgical methods such as peeling, middle layer skin grafting, punch grafting, and inhaled water grafting.
본 발명은 홍경천 추출물을 유효성분으로 포함하는 신규한 백반증 치료 건강기능식품 조성물에 관한 것으로, 음식물을 통하여 난치성 질환인 백반증 치료효과가 있다는 점에서 상술한 종래 기술과는 상이하다.
The present invention relates to a novel functional food composition for treatment of vitiligo comprising an extract of Rhodiola grisea as an active ingredient and is different from the above-mentioned conventional art in that it has an effect of treating vitiligo, a refractory disease, through food.
홍경천(학명: Rhodiola Sachalinensis A. Bor)은 고산지대에서 자라는 다년생 약용식물로 아시아의 서부와 북부에 분포되어 있으며, 분류학상으로 피자식물문 돌나물과 돌꽃속에 속하며, 백두산 지역에 자생하는 참돌꽃(R.sachalinenesis), 바위돌꽃(R.rosea), 가지돌꽃(R.ramosa), 좁은 입돌꽃(R.angusta), 돌꽃 (R.elongata) 등을 홍경천이라고 한다. 홍경천은 산소가 부족하고 온도가 낮으며 건조한 지역, 자외선이 강하게 비치는 낮과 밤의 기온차이가 매우 큰 해발이 높은 곳에서만 자생하며, 따라서 홍경천은 악조건의 자연에서 생존할 수 있는 특수한 적응 능력이 있다. 홍경천의 주요한 효능과 적응증은 원기회복, 장수, 산소결핍증, 한랭, 피로, 주의력증강, 신체쇠퇴억제, 노인병, 체력, 지력, 혈압정상회복, 기억력, 각종 신경과민증, 관상동맥질환, 근무력증, 당뇨병, 각혈, 폐렴, 타박상, 화상에 유효하다고 알려져 있다. 홍경천은 항산화능이 뛰어나다고 알려져 있는데, 주요성분은 사리드로시드(salidroside) 및 배당체 타이로솔(p-tyrosol)이며, 그 외에 전분, 단백질, 지방, 탄닌, 플라본류 화학물 및 미량의 정유 등이 함유되어 있다.
Rhodiola Sachalinensis A. Bor is a perennial medicinal plant that grows in a high mountain region. It is distributed in western and northern parts of Asia. It is classified into pizza plants, .Sachalinenesis, R.rosea, R.ramosa, R.angusta, and R.elongata are called Hongkong. Hong Kyung Chun grows only in areas with low oxygen, low temperature and dry areas, high altitude with high temperature difference between day and night with strong ultraviolet rays, and thus Hong Kyung Chun has special adaptive ability to survive in the nature of bad conditions . The major efficacy and indications of Hong Kyung Chun are: recovery, longevity, oxygen deficiency, cold, fatigue, attention deficit, inhibition of body decline, geriatric disease, physical strength, intelligence, recovery of normal blood pressure, memory, various nervous disorders, coronary artery disease, It is known to be effective for blood, pneumonia, bruises, and burns. Hong-Kyung Chun is known to have excellent antioxidant ability. Its major components are salidroside and glycoside p-tyrosol, as well as starch, protein, fat, tannin, flavonoid chemicals and trace amounts of essential oils. .
한편, 홍경천과 관련된 종래 특허를 살펴보면, 특허등록 제265385호에서는 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물에 관한 기술이 공개되어 있다. 특허등록 제445404호에서는 홍경천 추출물을 포함하는 미백 조성물에 관한 기술이 공개되어 있다. 특허등록 제999872호에서는 홍경천 추출물을 유효성분으로 함유하는 바이러스 질환의 예방 및 치료용 약학적 조성물에 관한 기술이 공개되어 있다. 특허등록 제1147913호에서는 홍경천 추출물을 유효성분으로 하는 혈당 조절용 조성물에 관한 기술이 공개되어 있다. 특허등록 제179087호에서는 홍경천 추출물을 유효 성분으로 하는 혈중 알콜농도 저하용 조성물에 관한 기술이 공개되어 있다. 특허등록 제316790호에서는 고산 홍경천 추출물을 함유하는 간 섬유화 억제 조성물에 관한 기술이 공개되어 있다. 특허등록 제204166호에서는 홍경천 추출물을 함유하는 항스트레스 조성물에 관한 기술이 공개되어 있다.
On the other hand, according to the conventional patents related to Hong-Kyung Chun, the patent registration No. 265385 discloses a technique for extracting Hong-Kyung Chun which has the preventive and therapeutic effect of circulatory diseases. Patent Registration No. 445404 discloses a technique relating to a whitening composition comprising an extract of Hongkong Stream. Patent Registration No. 999872 discloses a technique relating to a pharmaceutical composition for the prevention and treatment of viral diseases containing an extract of Rhodiola as an active ingredient. Patent Registration No. 1147913 discloses a technique relating to a composition for controlling blood glucose level, which comprises an extract of Hongkryung River as an active ingredient. Patent Registration No. 179087 discloses a technique for a composition for lowering the blood alcohol concentration using an extract of Rhodiola as an active ingredient. Patent No. 316790 discloses a technique relating to an inhibitor of hepatic fibrosis, which comprises a extract of Gochan Hongikyung River. Patent No. 204166 discloses a technique for an anti-stress composition containing a Rhodiola extract.
상기 특허들을 비롯한 선행기술들은 홍경천 추출물을 이용하여 미백, 바이러스질환, 혈당 조절, 혈중 알콜농도 저하, 항스트레스 등의 효능에 관한 기술을 공개하고 있으나, 홍경천의 백반증 치료에 관한 직접적 기술이나 암시된 바가 없다.
Prior arts including the above-mentioned patents disclose technologies relating to whitening, viral diseases, blood glucose control, lowering of blood alcohol concentration, antistress, etc. by using a Hongkong stream extract. However, direct techniques for treatment of vitiligo by Hong Kyung Chun none.
또한, 항산화 효과를 갖는 성분이 백반증에도 효과가 있을 거라는 연구가 있었으나, 본 발명자가 멜라닌세포에 도파민으로 세포특성을 일으킨 백반증 유사 세포모델에서 비타민C나 토코페롤 등 대표적인 항산화제들을 투여했으나 아무런 세포보호효과를 발견할 수 없어, 단순히 항산화 효과를 갖는 물질로부터 백반증 치료 효과를 기대할 수 없다는 것을 확인하였다. 즉, 항산화 효과를 갖는다고 알려진 홍경천으로부터 본 발명과 같은 백반증 치료 효과가 있다는 것을 용이하게 예측할 수 없다.
In addition, although studies have been made that a component having an antioxidant effect may be effective against vitiligo, the present inventors administered representative antioxidants such as vitamin C and tocopherol in a vitriol-like cell model in which melanocytes were caused to develop cell characteristics as dopamine, Can not be found, and it is confirmed that the effect of treatment of vitiligo can not be expected from a substance having an antioxidative effect simply. That is, it can not be easily predicted that the effect of treatment of vitiligo as in the present invention is obtained from Hong Kyung Chun, which is known to have an antioxidative effect.
본 발명은 백반증 치료 효과가 있는 건강기능성 식품 조성물을 제공하는 것을 목적으로 한다. It is an object of the present invention to provide a health functional food composition which is effective for treatment of vitiligo.
특히, 천연물질을 이용하여 백반증 치료 효과가 있는 건강기능성 식품 조성물을 제공하는 것을 목적으로 한다.
In particular, it is an object of the present invention to provide a health functional food composition which is effective for treatment of vitiligo by using a natural substance.
본 발명은 홍경천 추출물을 유효성분으로 포함하는 백반증 치료용 건강기능식품 조성물을 제공한다.
The present invention provides a health functional food composition for treating vitiligo comprising an extract of Rhodiola as an active ingredient.
특히, 상기 홍경천 추출물은 알콜로부터 추출된 용매 추출물인 것이 바람직하다.
In particular, it is preferable that the Rhodiola extract is a solvent extract extracted from alcohol.
특히, 상기 조성물 중 홍경천은 0.01 ~ 100 중량%로 사용 가능하다.
In particular, the composition of the present invention can be used in an amount of 0.01 to 100% by weight.
특히, 상기 조성물은 보조 성분으로 비타민, 미네랄, 인지질 또는 아미노산을 더 포함할 수 있다.
In particular, the composition may further comprise vitamins, minerals, phospholipids or amino acids as auxiliary components.
본 발명의 건강기능식품 조성물은 홍경천 추출물을 유효성분으로 하여 백반증 치료 효과를 갖는다. 본 발명에서는 실험을 통해 사람 정상 멜라닌세포에 홍경천을 처리했을 때 세포 활성이 높아져, 백반증 병변 내 멜라닌 세포나 병변과 인접한 정상부위의 멜라닌 세포의 활성을 올려 멜라닌 합성을 증가시킬 수 있을 것이라는 것을 간접적으로 확인하였으며, 또한, 사람 정상 멜라닌세포에 홍경천 추출물을 처리했을 때, 인산화된 ERK 효소가 증가하였음을 확인하였는데, 이러한 인산화된 ERK 효소의 증가를 통해 멜라닌세포 활성을 올려 백반증 치료 효과가 있을 것이라는 것을 간접적으로 확인할 수 있었다. 또한, 홍경천 추출물을 복용한 후 백반증 환자의 이마와 팔 부위의 백반증이 치료되는 것을 직접적으로 확인할 수 있었다.
The health functional food composition of the present invention has an effect of treating vitiligo with the extract of Rhodiola as an active ingredient. In the present invention, it has been experimentally demonstrated that when the human normal melanocyte is treated with the Hongkong stream, the cell activity is increased, and melanin cells in the vitiligo lesion or the melanin cell in the normal region adjacent to the lesion are increased, In addition, it was confirmed that phosphorylated ERK enzyme was increased when human normal melanocyte was treated with the Hongkryun extract, and it was confirmed that the increase of melanocyte activity through the increase of phosphorylated ERK enzyme would be effective for treatment of vitiligo Respectively. In addition, we could directly confirm the treatment of vitiligo in the forehead and arm of vitiligo patients after taking the Hongkong stream extract.
도 1은 실험예 1의 결과로서, 본 발명의 홍경천 추출물이 멜라닌세포의 증식을 유도한 결과를 보여주고 있다.
도 2는 실험예 2의 결과로서, 본 발명의 홍경천 추출물이 세포활성에 도움이 되는 ERK의 활성화를 유발한 결과를 보여주고 있다.
도 3a 및 3b는 실험예 3의 결과로서, 도 3a 및 3b는 각각 이마 부분과 팔 부분의 백반증 치료 효과에 대한 임상 실험 결과이다.FIG. 1 shows the results of Experimental Example 1, in which the Rhodiola extract of the present invention induced melanocyte proliferation.
FIG. 2 shows the results of Experimental Example 2, wherein the Rhodiola extract of the present invention induced activation of ERK, which is useful for cell activation.
FIGS. 3A and 3B are the results of Experimental Example 3, and FIGS. 3A and 3B are clinical experimental results on the treatment of vitiligo treatment of forehead and arm portions, respectively.
난치성 질환인 백반증은 멜라닌세포가 파괴되어 발생하는 질환으로 본 발명에서는 홍경천 추출물을 분리하고 멜라닌세포에 보호효과가 있는지 알아본 후 실제로 백반증 환자에 적용하여 임상효능을 확인하여 본 발명을 완성하였다.
The refractory disease, vitiligo, is a disease caused by the destruction of melanocytes. In the present invention, the extract of Rhizopus japonicus is isolated and examined for its protective effect on melanocytes, and then applied to patients with vitiligo to confirm clinical efficacy.
본 발명자는 특허등록 제445404호를 통하여 홍경천 추출물을 유효성분으로 하는 미백 조성물에 관한 기술을 공개한 바 있으나, 본 발명에서는 홍경천 추출물의 백반증 치료 용도에 대해서 확인하였다. 미백 효과는 멜라닌세포가 급속히 증가하는 것을 방지하는 효과이며, 백반증은 색소가 소실되는 질환으로서, 작용 기전이 상이한 기술인 바, 상기 본 발명자의 등록특허와 같은 홍경천의 미백효과를 통해 백반증 치료 효과를 용이하게 예측 불가능함을 밝혀둔다.
The present inventor has disclosed a technique relating to a whitening composition comprising an extract of Hongkryung Stream as an active ingredient through Patent Registration No. 445404, but in the present invention, the use of the extract of Hongkryuncheon for the treatment of vitiligo has been confirmed. The whitening effect is an effect to prevent the rapid increase of melanocytes. The vitrakin is a disease in which the pigment disappears, and the mechanism of action is different. As a result of the whitening effect of Hong Kyung Stream like the registered patent of the present inventor, It is unforeseeable.
본 발명에서 사용되는 홍경천 추출물은 통상적인 추출방법에 의해 얻을 수 있다. 예를 들어, 홍경천을 그늘에서 충분히 말린 뒤, 절단기로 세절하거나 분쇄기로 분쇄하여 추출물의 출발물질을 만든다. 상기 출발물질에 추출용매(에탄올 등의 알콜, 열수 등)를 가하여 실온에서 유효 성분을 추출한 다음, 고형물은 여과하여 제거하고, 여액은 감압 농축시킨다.
The Rhodiola extract used in the present invention can be obtained by a conventional extraction method. For example, dried red gypsum in the shade, and then crushed with a cutter or crushed by a grinder to make the starting material of the extract. An extraction solvent (alcohol such as ethanol, hot water, etc.) is added to the starting material and the active ingredient is extracted at room temperature. The solid material is removed by filtration, and the filtrate is concentrated under reduced pressure.
본 발명의 조성물에서 유효성분인 홍경천은 0.01 중량% 내지 100 중량%의 범위로 사용 가능한데, 특히, 홍경천 100 중량%인 경우 음용시 별도로 물과 같은 액상과 혼합하여 음용하면 된다.
The active ingredient of the composition of the present invention may be used in an amount of 0.01 to 100% by weight. In particular, when 100% by weight of Hongyeong Stream is used for drinking, it may be mixed with a liquid such as water separately for drinking.
이하에서는 실험예를 통해 본 발명의 효과에 대하여 설명하기로 한다.
Hereinafter, the effects of the present invention will be described with reference to experimental examples.
[[ 실험예Experimental Example ]]
이하 실험예에서 사용한 홍경천 분말은 건조된 홍경천을 물로 세척한 후 잘게 부수고 유효성분의 파괴를 막기 위하여 90℃ 이하의 온도 조건에서 80% 에탄올에 넣고 홍경천으로부터 유효성분을 추출한 후 여과하였으며, 이후 감압 농축하여 홍경천 분말을 얻어 이하 실험예에서 사용하였다.
In order to prevent destruction of the active ingredient, the dried red ginseng powder was washed with water and dried to remove the active ingredient. The active ingredient was extracted from the red ginseng by adding 80% ethanol at a temperature of 90 ° C or less and then filtered. And the obtained powder was used in the following experimental examples.
[[ 실험예Experimental Example 1] One] 홍경천Hong Kyung Chun 추출물에 의한 세포증식효과 Effect of Extract on Cell Proliferation
홍경천 분말을 이용하여 세포증식효과를 실험하였다. 세포증식효과는 MTT 분석법을 사용하였다. 증식기의 정상 멜라닌세포를 웰 당 1,000개로 96 웰 플레이트에 접종하고, 200 ㎕의 멜라닌세포 배양용액(MGM)에서 24시간 배양하였다. 상기 배지에 용해되어 있는 홍경천 추출물의 최종 농도가 각각 0, 1, 10, 100 ㎍/㎖이 되도록 48시간 반응시켰다. 상기 혼합액을 MTT 용액 0.5 ㎎/㎖를 포함한 배지에서 4 시간 배양한 뒤, 200 ㎕ 디메틸설폭사이드 용액을 웰에 넣고 용해시켜, ELISA 판독기를 사용하여 540 ㎚에서 흡광도를 측정하였고, 각 용액의 세포 증식율을 하기 계산식 1로 환산하였다.
The effect of cell proliferation was examined by using Hongkong Stream Powder. MTT assay was used for cell proliferation effect. Normal melanocytes of the proliferating cells were inoculated into 96 well plates at 1,000 per well and cultured in 200 μl of melanocyte culture solution (MGM) for 24 hours. The reaction was carried out for 48 hours so that the final concentrations of the Rhodiola extract dissolved in the medium were 0, 1, 10, and 100 쨉 g / ml, respectively. The mixed solution was incubated in a medium containing 0.5 mg / ml of MTT solution for 4 hours, 200 μl of dimethylsulfoxide solution was added to the well and dissolved, and the absorbance at 540 nm was measured using an ELISA reader. The cell proliferation rate Was converted into the following equation (1).
[계산식 1][Equation 1]
세포증식율(%)=(실험군의 흡광도/대조군의 흡광도) x 100
Cell proliferation rate (%) = (absorbance of experimental group / absorbance of control group) x 100
첨부된 도 1은 홍경천 추출물을 함유하지 않는 대조군을 100%로 표시하였을 경우의 세포증식 및 생존율을 나타낸다. 도 1의 결과로부터, 홍경천 추출물이 백반증 병변 내 멜라닌 세포나 병변과 인접한 정상부위의 멜라닌 세포의 활성을 높여 멜라닌 합성을 증가시킴으로써 백반증 치료 효과가 있을 것이라는 것을 알 수 있었다.
FIG. 1 shows the cell proliferation and survival rate when 100% of the control group not containing the Rhodiola extract was expressed as 100%. From the results shown in Fig. 1, it was found that the extract of Hongryongcheon enhances the activity of melanocytes in the normal region adjacent to the melanocytes or lesions in the vitiligo lesion, thereby increasing the melanin synthesis, thereby being effective for treatment of vitiligo.
[[ 실험예Experimental Example 2] 2] 홍경천Hong Kyung Chun 추출물에 의한 By extract MAPKMAPK 변화 change
홍경천 추출물이 ERK를 활성화하는지 관찰하였다. 60 mm 플레이트에 5.0 x 105 개의 세포를 뿌린 후 10% FBS가 포함된 MGM 배지에서 confluency가 70-80% 되게 배양하였다. 24시간 동안 기아(starvation) 시키고 홍경천 추출물을 처리하고(100 ㎍/㎖) 실험에 적용된 시간별로 세포를 회수하였다. DPBS로 2번 세척한 후 lysis buffer(62.5 mM Tris-HCl, pH6.8, 2% SDS, 5% b-mercaptoethanol, 2 mM phenylmethysulfonyl fluoride (PMSF), 1 mM Na3VO4, 50 mM NaF, 10 mM EDTA, Complete protease inhibitor (Roche, Mannheim, Germany))를 첨가하여 단백질을 추출하고 브래드포드어세이(Bradford assay)로 단백질을 정량하였다. 같은 양의 단백질을 취하여 12% SDS-polyacrylamide gel에 로딩한 후 125 V에서 90분 동안 전기영동을 실시하였다. 분리된 단백질을 PVDF 멤브레인(Immobilon, Millipore, Bedford, MA, USA)으로 이동시킨 후 일차항체와 이차항체를 반응시키고 ECL 키트(Enhanced chemiluminescence kit, Amersham, Princeton, NJ, USA)를 이용하여 현상하였다.
We examined whether the Hongkong stream extract activates ERK. 5.0 × 10 5 cells were plated on 60 mm plates and cultured in confluency with 70-80% in MGM medium containing 10% FBS. The cells were starvated for 24 hours, treated with the extract of Hongkryeong (100 ㎍ / ml) and the cells were recovered by the time applied in the experiment. After washing twice with DPBS, the cells were washed with lysis buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 5% b- mercaptoethanol, 2 mM phenylmethysulfonyl fluoride (PMSF), 1 mM Na3VO4, 50 mM NaF, Complete protease inhibitor (Roche, Mannheim, Germany) was added to extract the protein and quantify the protein by the Bradford assay. The same amount of protein was loaded on 12% SDS-polyacrylamide gel and electrophoresed at 125 V for 90 minutes. The separated proteins were transferred to a PVDF membrane (Immobilon, Millipore, Bedford, Mass., USA), reacted with the primary antibody and secondary antibody, and developed using an ECL kit (Enhanced chemiluminescence kit, Amersham, Princeton, NJ, USA).
MAP kinase 경로 중 ERK 경로는 세포성장인자, 싸이토카인 등을 인지하여 세포 내로 증식, 생존에 관련한 신호를 전달하는 것으로 알려져 있다. 이를 확인하기 위해 홍경천 추출물을 처리하고 2, 10, 30, 60, 180, 360분 간격으로 ERK의 단백질 인산화를 관찰하였다. ERK의 경우 홍경천 추출물 처리 후 2분부터 인산화되어 360분까지 지속하였다(도 2 참조).
The ERK pathway in the MAP kinase pathway is known to recognize cell growth factors, cytokines, etc., and to transmit signals related to proliferation and survival into cells. In order to confirm this, we examined the protein phosphorylation of ERK at 2, 10, 30, 60, 180, and 360-minute intervals. ERK was phosphorylated from 2 minutes after treatment with Hongkryuncheong extract and continued for 360 minutes (see Fig. 2).
따라서, 본 발명의 홍경천 추출물은 멜라닌세포의 증식효과가 있고 ERK의 상승작용이 있으므로 멜라닌세포의 사망에 의한 백반증의 치료보조효과가 있을 것으로 추정가능하다.
Therefore, it is presumed that the Rhodiola extract of the present invention has a proliferative effect on melanocytes and a synergistic effect on ERK, so that there is a therapeutic effect for the treatment of vitilus caused by death of melanocytes.
[[ 실험예Experimental Example 3] 백반증 환자에 적용 실험 3] Application to patients with vitiligo
도 3a 및 3b는 본 발명의 홍경천 추출물이 백반증 환자에게서 병변을 회복시킨 임상적 결과로서, 도 3a는 이마 부분, 도 3b는 팔 부분의 백반증 환자에 대한 임상 실험 결과이다.
FIGS. 3A and 3B are clinical results showing that the Rhodiola extract of the present invention restores lesions in patients with vitiligo. FIG. 3A shows the clinical results of the forehead part and FIG. 3B shows clinical results of vitiligo patients with the arm part.
백반증 환자에게 홍경천 분말 10%가 포함된 건강식품을 투여하고 8주 후 관찰한 결과 도 3a와 같이 투여 전 병변의 47% 수준으로, 도 3b에서 61% 수준으로 백반증의 호전을 관찰할 수 있었다. 특히 8주 후 병변의 윤곽이 줄어들었을 뿐만 아니라 병변 내에 피부색이 정상으로 회복되고 있는 영역들이 나타난 것을 관찰할 수 있었다. 이러한 결과를 볼 때 홍경천 추출물은 백반증의 호전에 도움이 되는 효능이 있는 것으로 판단된다.
As shown in FIG. 3A, after treatment with healthy food containing 10% of Rhodiola powder, vitiligo was observed in 47% of pre-administration lesions and 61% in FIG. 3b as shown in FIG. 3A. Especially after 8 weeks, we could observe that lesions were not only outlined but also recovered normal lesions. These results suggest that the extract of Hongkongcheon has the effect of helping the improvement of vitiligo.
지금까지 살펴본 바와 같이 홍경천 추출물은 백반증 치료에 효과가 있음을 알 수 있었다. 본 발명의 조성물은 홍경천에 종래의 음용 가능한 부형제 등을 첨가하여 제조될 수 있으며, 특히, 보조 성분으로 비타민B, 비타민C, 비타민E, 베타카로틴 등의 비타민류, Ca, Mg, Zn 등의 미네랄류, 레시틴 등의 인지질 또는 아미노산 등의 화합물을 사용할 수 있다. 또한, 천연색소 및 감미 성분 등을 혼합하여 사용할 수 있다.
As we have seen so far, we found that the extract of Hongkongcheon is effective in the treatment of vitiligo. The composition of the present invention can be prepared by adding a conventional drinkable excipient or the like to the Hongryong Stream, and in particular, vitamin A, vitamin C, vitamin E and beta-carotene as vitamins such as vitamin B, minerals such as Ca, Mg and Zn , Phospholipids such as lecithin, and amino acids. In addition, a natural coloring matter and a sweetening component may be mixed and used.
또한, 본 발명의 조성물은 엑기스제, 분말제, 과립제, 캡슐제 등의 제형으로 제조 가능하다.
In addition, the composition of the present invention can be manufactured into formulations such as an extract, a powder, a granule, a capsule and the like.
Claims (4)
A health functional food composition for treatment of vitiligo comprising an extract of Hongkong Stream as an active ingredient.
The health functional food composition for treating vitiligo according to claim 1, wherein the Rhodiola extract is a solvent extract extracted from alcohol.
The health functional food composition for treating vitiligo according to claim 1, wherein the composition comprises 0.01 to 100% by weight of the composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140088831A KR20160008752A (en) | 2014-07-15 | 2014-07-15 | Functional food composition for treating vitiligo containing rhodiola sachalinensis as active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140088831A KR20160008752A (en) | 2014-07-15 | 2014-07-15 | Functional food composition for treating vitiligo containing rhodiola sachalinensis as active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160008752A true KR20160008752A (en) | 2016-01-25 |
Family
ID=55306729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140088831A KR20160008752A (en) | 2014-07-15 | 2014-07-15 | Functional food composition for treating vitiligo containing rhodiola sachalinensis as active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160008752A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0179087B1 (en) | 1995-12-21 | 1999-03-20 | 백운화 | Composition containing rhodiola sachalinesis extract for lowering blood alcohol concentration |
| KR100204166B1 (en) | 1996-07-26 | 1999-06-15 | 윤재승 | Composition for anti-stress |
| KR100265385B1 (en) | 1998-02-27 | 2000-11-01 | 윤여표 | Extract of rhodiola sp. for prevending and treating circulating diseases |
| KR100316790B1 (en) | 1999-12-21 | 2002-01-17 | 손동환 | A composition having an effect of preventing liver fibrosis by containing a extract of Rhodiola sachalinensis A. Bor |
| KR100445404B1 (en) | 2001-08-01 | 2004-08-25 | 주식회사 웰스킨 | Whitening composition containing rhodiola sachalinensis a. bor extraction |
| KR100999872B1 (en) | 2008-06-12 | 2010-12-09 | 한국생명공학연구원 | Pharmaceutical compositions for prevention and treatment of viral diseases containing rodiola extracts, fractions, the isolated flavonoid compounds therefrom, derivatives compounds thereof or the pharmaceutically acceptable salts as an active ingredient |
| KR101147913B1 (en) | 2005-09-07 | 2012-05-25 | 씨제이제일제당 (주) | Composition for controlling blood glucose level |
-
2014
- 2014-07-15 KR KR1020140088831A patent/KR20160008752A/en not_active Application Discontinuation
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0179087B1 (en) | 1995-12-21 | 1999-03-20 | 백운화 | Composition containing rhodiola sachalinesis extract for lowering blood alcohol concentration |
| KR100204166B1 (en) | 1996-07-26 | 1999-06-15 | 윤재승 | Composition for anti-stress |
| KR100265385B1 (en) | 1998-02-27 | 2000-11-01 | 윤여표 | Extract of rhodiola sp. for prevending and treating circulating diseases |
| KR100316790B1 (en) | 1999-12-21 | 2002-01-17 | 손동환 | A composition having an effect of preventing liver fibrosis by containing a extract of Rhodiola sachalinensis A. Bor |
| KR100445404B1 (en) | 2001-08-01 | 2004-08-25 | 주식회사 웰스킨 | Whitening composition containing rhodiola sachalinensis a. bor extraction |
| KR101147913B1 (en) | 2005-09-07 | 2012-05-25 | 씨제이제일제당 (주) | Composition for controlling blood glucose level |
| KR100999872B1 (en) | 2008-06-12 | 2010-12-09 | 한국생명공학연구원 | Pharmaceutical compositions for prevention and treatment of viral diseases containing rodiola extracts, fractions, the isolated flavonoid compounds therefrom, derivatives compounds thereof or the pharmaceutically acceptable salts as an active ingredient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lim et al. | Protective effect of the standardized green tea seed extract on UVB-induced skin photoaging in hairless mice | |
| KR20110108687A (en) | Skin whitening agent containing extracts of natural materials and composition of cosmetic | |
| KR20170080336A (en) | Radish, lotus root and a red bit alcoholic extract consisting of anti-inflammatory composition | |
| US10391137B2 (en) | Platelet-derived growth factor-BB production promotor, and mesenchymal stem cell production accelerator, stem cell stabilizer and dermal regenerator comprising the same | |
| WO2009110546A1 (en) | Composition containing aqueous extract of ashwaganda leaves as the active ingredient and method of producing the same | |
| JP6513468B2 (en) | A skin external preparation or an internal preparation containing an extract of red beet grown by irradiation with light having a specific wavelength range. | |
| KR101863297B1 (en) | Composition for preventing or improving skin wrinkle comprising chlorogenic acid and rutin compound as active ingredient | |
| KR20160141757A (en) | Composition for external application | |
| KR20160011732A (en) | Extraction method extracting Sea Buckthorn leaves extracts by low-temperature ripening extracts and anti-oxidant activation and cosmetic compositions with superior whitening effect by the extraction method | |
| KR102094667B1 (en) | Composition for anti-aging comprising Rhodobacter sphaeroides strain or culture solution of the strain | |
| JP6595192B2 (en) | A skin external preparation or an internal preparation containing an extract of fenugreek cultivated by irradiation with light having a specific wavelength range. | |
| KR20220004328A (en) | Composition for maintaining the balance of microbiome in the skin comprising hampseed oil | |
| KR20210045695A (en) | Composition for Inducing Autophagy Activity Comprising 2-Fucosyllactose | |
| KR102379523B1 (en) | Composition comprising an extract of Astragalus membranaceus showing the effect of protecting neuronal cell | |
| KR101456059B1 (en) | The cosmetic composition effective in whitening and anti-aging mainly comprised of roasted licorice extract | |
| KR20160008752A (en) | Functional food composition for treating vitiligo containing rhodiola sachalinensis as active ingredient | |
| KR20140052127A (en) | Skin wrinkle improving cosmetic compositions containing enzymaticallly hydrolyzed apple extract | |
| JP5689552B1 (en) | A skin external preparation or an internal preparation containing an extract of chamomile grown by irradiating light having a specific wavelength range. | |
| KR101677460B1 (en) | Cosmetic composition comprising allergen removed water soluble royal jelly for skin whitening and anti-aging activity | |
| KR20210039657A (en) | Composition for Inducing Autophagy Activity Comprising Cellobiose | |
| JP2014129338A (en) | Hand-foot syndrome therapeutic composition | |
| KR102419102B1 (en) | New composition comprising exosomes derived from Malus as an active ingredient | |
| KR102582377B1 (en) | Composition comprising zizania latifolia extract for inhibiting or preventing skin disease and skin damage caused by ultroviolet a | |
| KR102135071B1 (en) | Uses of pyrenaria buisanensis extract | |
| KR102474322B1 (en) | Skin external composition containing extract of yellow-colored leaf of soybean grown by removing bean pods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |